Literature DB >> 15588349

Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations.

Michael Vajdy1, Manmohan Singh, Jina Kazzaz, Elawati Soenawan, Mildred Ugozzoli, Fengmin Zhou, Indresh Srivastava, Qian Bin, Susan Barnett, John Donnelly, Paul Luciw, Lou Adamson, David Montefiori, Derek T O'Hagan.   

Abstract

There is an urgent need to develop vaccines that can elicit immunological memory responses against HIV. Using the rhesus macaque model and a combination of intranasal (IN) and parenteral immunizations with DNA or protein adsorbed to microparticles or mixed with mucosal adjuvants we sought to induce anti-HIV memory-type immune responses in both the mucosal and systemic compartments. Prime/boost immunizations were performed through five IN immunizations alone with HIV-env oligomeric gp140 (Ogp140) or HIV-gag-p24 mixed with Escherichia coli heat labile-derived mutant adjuvants or two parenteral immunizations with DNA encoding HIV-env or -gag adsorbed to microparticles followed by three IN immunizations with p24 gag protein and the mutant adjuvants. Both modes of immunizations induced anti-gp140 plasma and vaginal IgG and IgA as well as interferon (IFN)-gamma secreting peripheral blood mononuclear cells (PBMC) after HIV-env and -gag peptide restimulation. After a resting period of 4 months, when the levels of humoral and cellular responses had decreased, intramuscular (IM) booster immunizations with p55-gag protein adsorbed to microparticles and Ogp140 in MF59 oil in water emulsion significantly enhanced anti-HIV plasma and vaginal antibody, as well as peripheral blood IFN-gamma responses in all groups of vaccinated macaques. Importantly, plasma neutralization activity against both homologous and heterologous HIV strains was observed in all groups following the IM booster immunizations with protein. These findings show that IN priming alone or combinations of parenteral and IN immunizations followed by IM booster immunizations hold promise to significantly enhance mucosal and systemic memory-type immune responses against HIV-1 antigens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15588349     DOI: 10.1089/aid.2004.20.1269

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  19 in total

1.  Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.

Authors:  Lan Wu; Wing-Pui Kong; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.

Authors:  Pooja Ralli-Jain; Delia Tifrea; Chunmei Cheng; Sukumar Pal; Luis M de la Maza
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

3.  Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations.

Authors:  Claudia Pastori; Lorenzo Diomede; Assunta Venuti; Gregory Fisher; Jonathan Jarvik; Morgane Bomsel; Francesca Sanvito; Lucia Lopalco
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

4.  Purification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaques.

Authors:  Thomas Musich; Thorsten Demberg; Ian L Morgan; Jacob D Estes; Genoveffa Franchini; Marjorie Robert-Guroff
Journal:  Clin Immunol       Date:  2015-04-01       Impact factor: 3.969

5.  A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

Authors:  Paul Spearman; Michelle A Lally; Marnie Elizaga; David Montefiori; Georgia D Tomaras; M Juliana McElrath; John Hural; Stephen C De Rosa; Alicia Sato; Yunda Huang; Sharon E Frey; Paul Sato; John Donnelly; Susan Barnett; Lawrence J Corey
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

6.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

7.  Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments.

Authors:  Peter A Anton; F Javier Ibarrondo; W John Boscardin; Ying Zhou; Elissa J Schwartz; Hwee L Ng; Mary Ann Hausner; Roger Shih; Julie Elliott; Patricia M Hultin; Lance E Hultin; Charles Price; Marie Fuerst; Amy Adler; Johnson T Wong; Otto O Yang; Beth D Jamieson
Journal:  Vaccine       Date:  2008-06-17       Impact factor: 3.641

8.  Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery.

Authors:  Amanda Goodsell; Fengmin Zhou; Soumi Gupta; Manmohan Singh; Padma Malyala; Jina Kazzaz; Catherine Greer; Harold Legg; Tony Tang; January Zur Megede; Ranjana Srivastava; Susan W Barnett; John J Donnelly; Paul A Luciw; John Polo; Derek T O'Hagan; Michael Vajdy
Journal:  Immunology       Date:  2007-10-17       Impact factor: 7.397

9.  Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.

Authors:  Shixia Wang; Jeffrey S Kennedy; Kim West; David C Montefiori; Scott Coley; John Lawrence; Siyuan Shen; Sharone Green; Alan L Rothman; Francis A Ennis; James Arthos; Ranajit Pal; Phillip Markham; Shan Lu
Journal:  Vaccine       Date:  2008-07-23       Impact factor: 3.641

Review 10.  Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.

Authors:  Thorsten Demberg; Marjorie Robert-Guroff
Journal:  Int Rev Immunol       Date:  2009       Impact factor: 5.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.